# Duoning

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/duoning

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.duoningbio.com
- Latest round: Series C (Nov 25, 2021)
- Investors on record: 7

## About

Based in Shanghai, China and established in 2005, Duoning is a supplier of serum-free culture medium, disposable products, and bioreactor in biomedical industry. In 2018, Duoning Biotechnology incorporated the Beijing Tianguangshi Biotechnology Co., Ltd., realizing the layout of double engine R & D bases in Shanghai and Beijing. In 2019, Duoning Biotechnology realized the acquisition of Guangzhou Qizhi Bioengineering Equipment Co., Ltd., which was founded in 2008, and provides technological services for large-scale cultivation of animal cells by cell bioreactor to produce vaccines, antibodies and other products Business.

The company developed serum-free, personalized, chemical composition limited cell culture medium and animal cell culture process, and research, development and production of disposable production and bioreactor. meanwhile, It provides formula production, process optimization, process validation, technical support for the biopharmaceutical industry. Specific products includes basic culture media, such as S3, S3-CD, S4, media C for biomedical industry customers, as well as max series, AR8/BR8, DN feed 1/DN feed B, 2×103 feeding media and other medium series based on 2×103 supplements.

The company plans to continue to layout the industry chain, and to accelerate the establishment of a one stop supply platform.

## Funding rounds

- Series C, Nov 25, 2021 — Hong Shan, GL Capital Group, China Universal Capital Investment Fund, Lake Bleu Capital
- Series B, Dec 30, 2020 — Hong Shan, LYFE Capital, Lake Bleu Capital, Yaoming Biology fund
- Series A, Apr 24, 2019 — Ally Bridge Group

## Investors

- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series A
- Hong Shan — Series B, Series C
- LYFE Capital — Series B
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series B, Series C
- Yaoming Biology fund — Series B
- GL Capital Group (https://capitalatlas.ai/funds/gl-capital-group) — Series C
- China Universal Capital Investment Fund (https://capitalatlas.ai/funds/china-universal-capital-investment-fund) — Series C